PROTECT PHARMACEUTICAL Corp (PRTT) financial statements (2022 and earlier)

Company profile

Business Address 95 MERRICK WAY, THIRD FLOOR
CORAL GABLES, FL 33143
State of Incorp. NV
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in thousands)

6/30/2018
Q2
3/31/2018
Q1
12/31/2017
Q4
9/30/2017
Q3
6/30/2017
Q2
3/31/2017
Q1
12/31/2016
Q4
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments200     
Cash and cash equivalents200     
Total current assets:200     
Noncurrent Assets
TOTAL ASSETS:200     
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:11111110
Interest and dividends payable141062   
Other undisclosed accounts payable and accrued liabilities(12)(9)(5)(2)1110
Due to related parties36353535353511
Other undisclosed current liabilities141062   
Total current liabilities:51464239363621
Noncurrent Liabilities
Long-term debt and lease obligation121101101101100  
Long-term debt, excluding current maturities121101101101100  
Total noncurrent liabilities:121101101101100  
Total liabilities:1721471431401373621
Stockholders' equity
Stockholders' equity attributable to parent(152)(147)(143)(140)(137)(36)(21)
Common stock6666666
Additional paid in capital9,3669,3669,3669,3669,3669,3669,366
Accumulated deficit(9,523)(9,518)(9,515)(9,511)(9,508)(9,407)(9,392)
Total stockholders' equity:(152)(147)(143)(140)(137)(36)(21)
TOTAL LIABILITIES AND EQUITY:200     

Income statement (P&L) ($ in thousands)

6/30/2018
Q2
3/31/2018
Q1
12/31/2017
Q4
9/30/2017
Q3
6/30/2017
Q2
3/31/2017
Q1
12/31/2016
Q4
Operating expenses(1)   (100)(0)(0)
Other undisclosed operating income (loss)     (15)5
Operating income (loss):(1)   (100)(15)4
Interest and debt expense(4)(4)(4)(3)(0)  
Income (loss) from continuing operations:(4)(4)(4)(3)(100)(15)4
Other undisclosed income before gain (loss) on sale of properties      21
Income (loss) before gain (loss) on sale of properties:(4)(4)(4)(3)(100)(15)26
Other undisclosed net loss      (46)
Net loss available to common stockholders, diluted:(4)(4)(4)(3)(100)(15)(20)

Comprehensive Income ($ in thousands)

6/30/2018
Q2
3/31/2018
Q1
12/31/2017
Q4
9/30/2017
Q3
6/30/2017
Q2
3/31/2017
Q1
12/31/2016
Q4
Net loss:(4)(4)(4)(3)(100)(15)(20)
Comprehensive loss, net of tax, attributable to parent:(4)(4)(4)(3)(100)(15)(20)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: